| Title | Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study |
| Authors | Lu, Yun Yang, Qing-qing Zhuo, Lin Yang, Kun Kou, Hao Gao, Su-yu Hu, Wen Jiang, Qiao-li Li, Wen-jing Wu, Dong-fang Sun, Feng Cheng, Hong Zhan, Siyan |
| Affiliation | Wuhan Univ, Dept Pharm, Zhongnan Hosp, Wuhan, Peoples R China Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing, Peoples R China Peking Univ Third Hosp, Res Ctr Clin Epidemiol, Beijing, Peoples R China |
| Keywords | LUNG INJURY AIRWAY INHALATION INFECTION |
| Issue Date | 6-Oct-2022 |
| Publisher | FRONTIERS IN MICROBIOLOGY |
| Abstract | Ambroxol is a commonly used mucolytic agent principally used to treat respiratory diseases, which may have a role as adjunctive therapy for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but there is lack of evidence about its effectiveness on coronavirus disease-2019 (COVID-19) patients. To study the association between ambroxol use and clinical outcomes among hospitalized patients of COVID-19 infection. We conducted a multicenter retrospective cohort study involving 3,111 patients with confirmed SARS-CoV-2 infection from three hospitals in Wuhan from 19 December 2019 to 15 April 2020, and the primary outcome was in-hospital mortality. COVID-19 patients were classified into ambroxol and non-ambroxol groups based on the administration of ambroxol during hospitalization. Two analyses including propensity score matching (PSM) to obtain a 1:1 balanced cohort and logistic regression were used to control for confounding factors. The average age of 3,111 patients was 57.55 +/- 14.93 years old, 127 of them died during hospitalization, and 924 of them used ambroxol. Treatment with ambroxol did not have a significant effect on in-hospital mortality of COVID-19 patients when compared with non-ambroxol in PSM model after adjusting for confounders (8.0% vs. 3.5%, adjusted OR, 1.03 [95% CI, 0.54-1.97], p = 0.936). Adverse events such as nausea/vomiting, headache, and rash were comparable between the two groups. Our results suggest that the use of ambroxol is not significantly associated with in-hospital mortality in COVID-19 patients, which provides evidence for evaluating the effects of ambroxol on COVID-19 patient outcomes and may be helpful for physicians considering medication alternatives for COVID-19 patients. |
| URI | http://hdl.handle.net/20.500.11897/657594 |
| DOI | 10.3389/fmicb.2022.1013038 |
| Indexed | SCI(E) |
| Appears in Collections: | 公共卫生学院 第三医院 |
